Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zafirlukast in Tumor-marker Only Relapsed Ovarian Cancer
NCT04339140Phase 2Completed
- Sponsor
- Beth Israel Deaconess Medical Center
- Start
- Jun 2020
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of zafirlukast in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by Beth Israel Deaconess Medical Center. Started Jun 2020; status: completed.
02
Drugs
zafirlukast
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04339140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339140.